Pulmatrix (PULM) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PULM shares.
View PULM analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued twelve-month price targets for Pulmatrix's shares. Their PULM share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 271.7% from the stock's current price.
View analysts price targets for PULM or view top-rated stocks among Wall Street analysts.

Pulmatrix's stock was trading at $3.88 on January 1st, 2023. Since then, PULM stock has decreased by 30.7% and is now trading at $2.69.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our PULM earnings forecast.

Pulmatrix, Inc. (NASDAQ:PULM) announced its quarterly earnings data on Thursday, March, 30th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.44) by $0.30. The biotechnology company earned $1.71 million during the quarter, compared to analyst estimates of $1.87 million. Pulmatrix had a negative net margin of 285.66% and a negative trailing twelve-month return on equity of 55.65%.

Pulmatrix's stock reverse split on the morning of Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

Pulmatrix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (6.02%) and Susquehanna International Group LLP (0.68%).
View institutional ownership trends.

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PULM stock can currently be purchased for approximately $2.69.

Pulmatrix (NASDAQ:PULM) has a market capitalization of $9.82 million and generates $6.07 million in revenue each year. The biotechnology company earns $-18,840,000.00 in net income (profit) each year or ($5.17) on an earnings per share basis.

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The official website for the company is www.pulmatrix.com. The biotechnology company can be reached via phone at (781) 357-2333, via email at rclarke@pulmatrix.com, or via fax at 707-525-9906.